ACN vs CTSH
Accenture and Cognizant, both Technology
Accenture is the larger company at $143B against $27B. On trailing earnings CTSH is the cheaper of the two at a P/E of 13.0 against 17.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year CTSH returned -9.4% against -9.6% for ACN.
| Figure | ACN | CTSH |
|---|---|---|
| Last close | $215 | $59.69 |
| Market cap | $143B | $27B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.2 | 13.0 |
| Dividend yield | 2.8% | 2.1% |
| 1-year return | -9.6% | -9.4% |
| 5-year return | -32% | -15% |
| RyuScoresector-relative, 1–10 | 82/100 | 82/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Accenture
Revenue of $19B in Q3 2026, net income $2.3B. Its largest reported line is Americas, 49% of the disclosed total.
Cognizant
Revenue of $5.4B in Q1 2026, net income $662M. Its largest reported line is Health Sciences, 32% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.